Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2

• Published in: Antiviral therapy 2011-01, Vol.16 (8), p.1297-1308
• Main Authors: SAUERBREI, Andreas, BOHN, Kathrin, HAMPRECHT, Klaus, HEIM, Albert, HOFMANN, Jörg, WEISSBRICH, Benedikt, SCHNITZLER, Paul, HOFFMANN, Dieter, ZELL, Roland, JAHN, Gerhard, WUTZLER, Peter
• Format: Article
• Language: English
• Subjects: acyclovir; Acyclovir - administration & dosage; Acyclovir - analogs & derivatives; Acyclovir - therapeutic use; Adolescent; Adult; Aged; Amino acid substitution; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biological and medical sciences; Bromodeoxyuridine - administration & dosage; Bromodeoxyuridine - analogs & derivatives; Bromodeoxyuridine - therapeutic use; Child; Child, Preschool; Cidofovir; Cross-resistance; Cytosine - administration & dosage; Cytosine - analogs & derivatives; Cytosine - therapeutic use; Data processing; DNA-directed DNA polymerase; DNA-Directed DNA Polymerase - genetics; double prime TK gene; Drug Resistance, Viral - genetics; Female; foscarnet; Foscarnet - administration & dosage; Foscarnet - therapeutic use; Gene polymorphism; Genotype; Herpes Simplex - drug therapy; Herpes Simplex - virology; Herpes simplex virus 1; Herpes simplex virus 2; Herpesvirus 1, Human - enzymology; Herpesvirus 1, Human - genetics; Herpesvirus 1, Human - isolation & purification; Herpesvirus 2, Human - enzymology; Herpesvirus 2, Human - genetics; Herpesvirus 2, Human - isolation & purification; Humans; Infant; Male; Medical sciences; Middle Aged; Mutation; Organophosphonates - administration & dosage; Organophosphonates - therapeutic use; Penciclovir; Pharmacology. Drug treatments; pol gene; Protein-tyrosine kinase; Sequence Analysis, DNA; Thymidine kinase; Thymidine Kinase - genetics; Viral Proteins - genetics
• ISSN: 1359-6535; 2040-2058
• DOI: 10.3851/IMP1870

Studies to verify correlations between phenotypes and genotypes of herpes simplex virus (HSV) are an important tool to establish a database of resistance-associated mutations. In this study, 32 acyclovir (ACV)-resistant clinical HSV-1 and 4 ACV-resistant clinical HSV-2 isolates were examined in parallel by both phenotypic and genotypic resistance testing. Additionally, five non-viable HSV-1 strains and two non-viable HSV-2 strains with clinical resistance were included in genotypic resistance analysis. All ACV-resistant HSV isolates showed cross-resistance to brivudin and penciclovir, and were sensitive to foscarnet and cidofovir. Acyclovir resistance was assigned to frameshift and single non-synonymous mutations of the thymidine kinase (TK) gene in 32 out of 37 HSV-1 strains and in 4 out of 6 HSV-2 strains. In three HSV-1 isolates, there were resistance-associated amino acid substitutions of the DNA polymerase (pol). Six substitutions in the TK and two in the DNA pol gene could not be attributed without doubt to either ACV resistance or natural gene polymorphism. Altogether, 10 resistance-related mutations in the TK and 1 in the DNA pol gene have not been reported previously. The novel non-synonymous mutations found in this study enrich the knowledge about the genetic alterations of TK and DNA pol genes in ACV-resistant clinical HSV strains. Together with data from the literature, the findings justify the generation of a HSV database that contains resistance mutations associated with ACV resistance phenotype.